Drug Trial Radar · NCT07825389
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
119
Planned (sponsor's estimate)
Start
Feb 2027
Primary completion
Feb 2030
Study completion Feb 2030
Sponsor
- Lead sponsor
- AbelZeta Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a global, multicenter, Phase 1b/2 study evaluating the safety and efficacy of C-CAR168, an autologous anti-CD20/BCMA chimeric antigen receptor T-cell therapy, in participants with progressive multiple sclerosis refractory to standard-of-care therapy. The study includes participants with secondary progressive multiple sclerosis (SPMS) and primary progressive multiple sclerosis (PPMS).
Conditions
- Multiple Sclerosis
- Primary Progressive Multiple Sclerosis
- Secondary Progress Multiple Sclerosis (SPMS)
- Primary Progressive Multiple Sclerosis (PPMS)
- MS
- MS (Multiple Sclerosis)
- Neuro-Degenerative Disease
- Neuro-Degenerative Diseases
- Autoimmune
Interventions
C-CAR168Drug
Autologous anti-CD20/BCMA chimeric antigen receptor T-cell therapy administered as a single intravenous infusion following lymphodepleting chemotherapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Severity of Treatment-Emergent Adverse EventsTime frame: Through Month 24
- Proportion of Participants With 6-Month Composite Confirmed Disability Progression (6m-cCDP) Through Month 12Time frame: Through Month 12
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Gilbert, Arizona
Research Site
La Jolla, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.